ArticleVaccines2021
Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms.Frontiers in immunology · 2026Review
- Bacillus spore showcasing key antigens of African swine fever potentializes a promising oral vaccine candidate.Applied microbiology and biotechnology · 2025Article
- Recent development of oral vaccines (Review).Experimental and therapeutic medicine · 2024Review
- Article
- Retraction: Sung et al. Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on RecombinantVaccines · 2022Article
- An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
- Retraction · 2022-11-01Investigation by Journal/Publisher · Lack of IRB/IACUC Approval and/or Compliance ·
- Retracted
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Various types of vaccines, such as mRNA, adenovirus, and inactivated virus by injection, have been developed to prevent SARS-CoV-2 infection. Although some of them have already been approved under the COVID-19 pandemic, various drawbacks, including severe side effects and the requirement for sub-zero temperature storage, may hinder their applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.